PLX

Business Context and Reporting Period

This Form 10-KSB covers the fiscal year ended December 31, 2004, for Orthodontix, Inc. (Note: The input metadata referenced "Protalix Biotherapeutics," but the filing text explicitly identifies the issuer as Orthodontix, Inc.). The Company is a shell entity that ceased its original orthodontic practice management operations in 1999 and terminated all affiliations with founding practices by 2001. Currently, the Company has no operating revenue and is focused exclusively on identifying and consummating a merger, acquisition, or business combination with an operating company, primarily in South Florida.

Key Financial Metrics

Liquidity: The Company held approximately $564,000 in cash and cash equivalents as of December 31, 2004, invested in money market accounts and overnight repurchase agreements. Management believes these funds are sufficient to cover operating expenses for at least the next twelve months.

Material Changes Versus Prior Period

• Net Loss Increase: Net loss increased by approximately $19,356 (from $140,714 in 2003 to $160,070 in 2004). This was driven primarily by an increase in General and Administrative (G&A) expenses from $143,135 to $165,582.
• Interest Income Decline: Interest income decreased from $6,671 in 2003 to $5,512 in 2004, attributed to lower market interest rates and reduced excess cash balances during the year.
• Cash Position Improvement: Despite operating losses, cash and cash equivalents increased significantly from $179,479 in 2003 to $563,713 in 2004. This increase was primarily due to the redemption of a Certificate of Deposit ($552,359) in 2004, which was not present in the 2003 cash flow profile.
• One-Time 2003 Expense: The 2003 results included a $4,250 loss on the collection of notes receivable related to the settlement of a note from a founding practice, which did not recur in 2004.

Guidance, Outlook, Risks, and Unusual Items

• Plan of Operation: Management devotes substantially all time to identifying merger or acquisition candidates. No revenue is expected until a business combination is consummated.
• Risks: There are no assurances that the Company will enter into a transaction in the near future, on favorable terms, or that funding sources will be available. The Company has an accumulated deficit of approximately $3.7 million.
• Accountant Change: PricewaterhouseCoopers LLP resigned as the independent auditor on November 12, 2004. The Company engaged Salberg & Co. on February 2, 2005. There were no disagreements with PwC regarding accounting principles or financial statement disclosure.
• Related Party Transactions: The Company occupies office space rent-free at the corporate offices of Transworld Investment Corporation (TIC), where the CEO and a Director are officers. The CFO is compensated by an accounting firm in which he is a shareholder.

Investor Verification Checklist

• Shell Status: Verify the Company has no active operations and relies entirely on a future merger for value creation.
• Cash Runway: Confirm the $563,713 cash balance is sufficient to sustain the current low burn rate (~$165k/year) for the projected 12-month period.
• Merger Progress: Investigate if any specific acquisition targets have been identified or if negotiations are underway, as none are detailed in the filing.
• Related Party Conflicts: Review the relationship between Orthodontix management and Transworld Investment Corporation (TIC) regarding the rent-free office arrangement and potential conflicts of interest in future deal sourcing.
• Auditor Transition: Review the audit report from the new auditor, Salberg & Co., to ensure no material weaknesses were identified during the transition.